Boston, Massachusetts
March 4–7, 2018


Community Liaison Subcommittee

Mark Hubbard
Mr Hubbard has lived with HIV/AIDS for 28 years and has served on various Vanderbilt University community advisory boards since 2001. He chaired the Tennessee Association of People With AIDS from 2004 to 2010 and has been its education liaison since. He was awarded 6 consecutive community educator scholarships to CROI and conducts CROI-based community research trainings for the Tennessee AIDS Education and Training Center. He currently serves as a community representative to the HVTN Efficacy Trials Working Group and the HVTN073 / HPTN081 “AMP” protocol team.

Jeff Taylor
Mr Taylor is a longtime HIV activist who lives in Palm Springs, California. He is active in HIV cure and AIDS malignancy advocacy. He is Cochair of the UCLA CARE Collaboratory Community advisory board and is a patient representative to the AMC and to its ANCHOR anal cancer screening study.

Morenike Ukpong, FWACS, MBA, BChD
Dr Ukpong is an associate professor at Obafemi Awolowo University and Coordinator of the New HIV Vaccine and Microbicide Advocacy Society (NHVMAS), a non-governmental organization focused on advocating and supporting the creation of a conducive environment for research, development of and access to new biomedical HIV prevention tools. She has over 22 year experience in the field of HIV advocacy, community engagement in HIV research, ethical conduct of HIV prevention research and translation of research to policy and programs with focus on key population and adolescents.

Lisa Diane White, MPH
Ms White is the Deputy Director at SisterLove, Inc. a nonprofit community based organization in Atlanta, Georgia, dedicated specifically to the education, prevention and support needs of women at risk for HIV/AIDS and other reproductive health issues. She has 26 years of experience in Black Women’s Health issues and their inclusion in community based participatory research. Lisa Diane has been an outspoken educator, activist and advocate for the advancement of women's health and status globally including access to clinical trials, microbicide development, vaccine awareness, and Pre-Exposure Prophylaxis.